Meropenem Iv Infusion Suppliers & Bulk Manufacturers
Available Forms: Powder for Reconstitution
Available Strengths: 500 mg, 1 g, 2 g in vials
Reference Brands: Merrem (US & EU)
Category:
Antibiotics
Meropenem IV inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to bacterial lysis. It offers broad-spectrum activity against resistant gram-negative and gram-positive bacteria, including Pseudomonas. Benefits include rapid, potent bactericidal effect, excellent tissue penetration, and use in critical infections, ensuring reliable, effective treatment in hospital settings.
Meropenem IV infusion is available in Powder for Reconstitution
and strengths such as 500 mg, 1 g, 2 g in vials.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Meropenem IV infusion is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Meropenem IV infusion can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Meropenem IV infusion is approved in the EU and US for severe bacterial infections including pneumonia, urinary tract infections, and intra-abdominal sepsis. In the EU, brands like Merrem are regulated by EMA with dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic options are available. Both regions require detailed dossiers including clinical trial results, quality assurance, and pharmacovigilance plans for approval and ongoing safety monitoring. Due to its critical role in combatting resistant bacteria, strict prescribing and monitoring guidelines are enforced. For expert help with regulatory dossiers, compliance, and registration, visit PharmaTradz. We enable seamless market access aligned with European and US standards.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing